India establishes inspection guidelines

Share this article:

India's drug regulator is implementing inspection guidelines. The Wall Street Journal reports that the regulator has established an inspection framework that may do away with the haphazard nature of recent inspections.

The FDA has banned imports from four Ranbaxy laboratories after uncovering massive transgressions, and its parent company Sun Pharmaceuticals has also had its share of FDA hand-slaps.

The WSJ notes the FDA has upped its inspections of late, with 111 last year, up from 98 in 2011 and 59 in 2009.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.